REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received an average recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $35.45.

A number of equities research analysts have weighed in on RGNX shares. Barclays decreased their price objective on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Tuesday, October 22nd. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $39.00 target price on shares of REGENXBIO in a report on Wednesday, September 4th.

Insiders Place Their Bets

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $130,466.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total value of $115,600.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $130,466.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Argeris N. Karabelas sold 10,100 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $13.51, for a total value of $136,451.00. Following the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $152,473.86. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,200 shares of company stock valued at $354,651 in the last 90 days. 13.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its stake in shares of REGENXBIO by 73.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 746 shares during the period. nVerses Capital LLC boosted its holdings in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of REGENXBIO during the 1st quarter worth about $56,000. Headlands Technologies LLC increased its stake in shares of REGENXBIO by 276.8% in the 1st quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 2,812 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the period. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Price Performance

Shares of RGNX stock opened at $9.06 on Wednesday. REGENXBIO has a one year low of $8.90 and a one year high of $28.80. The stock has a fifty day moving average price of $10.98 and a 200 day moving average price of $12.84. The stock has a market cap of $446.26 million, a P/E ratio of -1.54 and a beta of 1.21.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.24. The company had revenue of $22.30 million during the quarter, compared to the consensus estimate of $22.97 million. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.66) EPS. Equities research analysts anticipate that REGENXBIO will post -4.66 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.